Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.05. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
14.05. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.05. | Former Inhibikase leader launches new biotech for midstage Parkinson's asset | 1 | FierceBiotech | ||
14.04. | Inhibikase Therapeutics Appoints David McIntyre As CFO, Stock Up In Pre-market | - | RTTNews | ||
INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
14.04. | Inhibikase Therapeutics appoints new CFO | 2 | Investing.com | ||
14.04. | Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise | 1 | Seeking Alpha | ||
14.04. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
31.03. | H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock | 3 | Investing.com | ||
27.03. | Inhibikase Therapeutics GAAP EPS of -$1.16 | 1 | Seeking Alpha | ||
27.03. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
27.03. | Inhibikase Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
27.03. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
27.03. | Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity | 379 | GlobeNewswire (Europe) | BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor... ► Artikel lesen | |
24.02. | Inhibikase enhances leadership with new appointments | 1 | Investing.com | ||
18.02. | Inhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth | 162 | GlobeNewswire (Europe) | -- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON... ► Artikel lesen | |
18.02. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
04.02. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
30.01. | Inhibikase hits pause on Parkinson's program over efficacy as it prioritizes lung drug | 1 | FierceBiotech | ||
29.01. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
06.01. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ABBVIE | 166,00 | +1,22 % | Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise? | ||
TEVA | 15,450 | +2,32 % | Teva Pharmaceutical Industries Ltd: Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer | TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the pricing and early acceptance results of its previously announced... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 7,164 | -0,75 % | EyePoint advances with Duravyu Phase III trial | ||
BAUSCH HEALTH | 4,143 | +2,45 % | Bausch Health Companies Inc: Bausch Health Announces 2025 Annual Meeting of Shareholder Results | LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("Annual... ► Artikel lesen | |
ORGANIGRAM GLOBAL | 1,190 | +3,48 % | Organigram Global Inc. reicht 6-K Bericht bei der SEC ein | ||
QUANTUM BIOPHARMA | 12,000 | -0,83 % | Quantum BioPharma Clarifies It Has Not Changed Its Name | TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma"), a biopharmaceutical company dedicated to building a portfolio of innovative... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 4,680 | +2,18 % | Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress | Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four... ► Artikel lesen | |
JAZZ PHARMACEUTICALS | 95,92 | +0,84 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ... | Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 1,390 | -2,66 % | SELLAS Life Sciences Group, Inc.: SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting | - ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer - - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in... ► Artikel lesen | |
XORTX THERAPEUTICS | 0,824 | +1,48 % | XORTX gibt 3-Millionen-USD-Platzierung bekannt | - Erlös wird für die Weiterentwicklung der XORTX-Programme zur Gichtbehandlung verwendet -
CALGARY, AB, 19. Mai 2025 / IRW-Press / XORTX Therapeutics Inc. ("XORTX" oder das "Unternehmen")... ► Artikel lesen | |
MADRIGAL PHARMACEUTICALS | 252,50 | +5,43 % | Citizens JMP behält positive Einschätzung für Madrigal-Aktie bei | ||
BRIDGEBIO PHARMA | 34,220 | +2,12 % | Piper Sandler maintains overweight rating on BridgeBio Pharma stock | ||
VERONA PHARMA PLC ADR | 74,20 | +3,34 % | Regeneron-Aktie crasht nach COPD-Daten - Verona Pharma schießt auf Allzeithoch | Bittere Pille für Regeneron Pharmaceuticals. Das Unternehmen und der Entwicklungspartner Sanofi haben in der vergangenen Handelswoche mit frischen Spätphasen-Studiendaten zum COPD-Hoffnungsträger Itepekimab... ► Artikel lesen | |
OPUS GENETICS | 0,899 | +2,28 % | XFRA R3X1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILOPUS GENETICS DL-... ► Artikel lesen | |
RIGEL PHARMACEUTICALS | 17,900 | -2,72 % | Rigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2025 Financial Results and Provides Business Update | First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of... ► Artikel lesen |